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NITROGEN mustard is at present the agent outstanding in the chemotherapy
of malignant tumours. It furnishes the basis for most of the drugs prepared
since Gilman and Philips (1946) synthesised the compound, by substituting a
sulphide group for the amino group of mustard gas, and found it developed re-
missions of transplantable mouse lymphosarcoma. While the results it has
yielded in Hodgkin's disease, lymphosarcoma, and chronic leukaemias, must
not be undervalued (Goodman et al., 1946; Jacobson et al., 1946; Karnofsky,
1950), nitrogen mustard has proved to be ofno value in the treatment of carcino-
matous tumours.
Nitromin, prepared by Stahmann and Bergmann (1946) was the first nitrogen-
mustard derivative to have a more marked growth-inhibiting effect on Yoshida
sarcoma than nitrogen mustard itself, and to be of lesser toxicity (Ishidate,
Kobayashi, Sakurai, Sato and Yoshida; cit. Farber et al., 1956). In Japan,
Nitromin is being widely used in human therapy. Kimura and his co-workers
(cit. Farber et al., 1956) found that in addition to being ofavail in cases of chronic
leukaemia, it had a destructive effect on certain malignant tumours.
Another nitrogen-mustard derivative is Erysan (R48), an aromatic chloro-
ethylamine, first synthesised by Haddow and his co-workers (1948), which was
shown to be highly effective on the Walker carcinosarcoma. Matthews (1950~
reported its effectiveness in chronic myeloid and lymphoid leukaemia in humans,
and Videbaek and Kaae (1954) in such cases of Hodgkin's disease as had failed
to respond to X-ray treatment.
Everett, Roberts, and Ross (1953) synthesised N,N-di-(2-chloroethyl)-p-
aminophenyl-butyric acid, an aromatic nitrogen-mustard derivative, which
they labelled CB 1348. This compound was found considerably to inhibit the
growth of Walker tumours and according to Haddow (1954), to have a beneficial
effect on lymphoreticular tumours and haemoblastoses; its depressant effect on
bone marrow was less than that of nitrogen mustard and TEM, respectively.
Larionov (1957) reported good results obtained with Sarcolysin and Dopan.
Simultaneously with, but independently of Larionov and co-workers (1955),
Bergel and Stock (1954) also prepared sarcolysine dl-p-di(chloroethyl)-amino-
phenylalanine hydrochloride. It caused complete regression in two sarcomas of
the rat and one of the mouse, and had a marked inhibitory effect on the growth
of seven other mouse and rat tumours.
For some years Vargha has endeavoured to produce an agent of reduced
toxicity, by linking nitrogen mustard with a sugar. Of the many compoundsTUMOUR-INHIBITING ACTION OF DBM.
he has prepared 1,6-di-(2-chloroethylamino)-1,6-dideoxy-D-mannitol dihydro-
chloride has proved to be of good effect. Having been investigated in animal
experiments by Kellner and N6meth (1956) and tested clinically by Sellei and
Eckhardt (1958), it has been introduced in human therapy as Degranol (BCM).
MATERIALS AND METHODS
Twenty-three combinations of nitrogen mustard with sugar, prepared by
Vargha in the course ofthe last two years, were tested for their respective toxicity,
and studied in transplantable animal tumours for their growth-inhibiting action.
Of these, one compound, marked R13, the structural formula of which may be
represented as 1,6-di-(2-bromoethylamino)-1,6-dideoxy-D-mannitol dihydrobro-
mide (DBM), was found to be the most promising (Vargha and Horvath, 1959;
Balo6, Kendrey, Juhasz, Besznyak, 1959). This is a stable compound readily
soluble in water, ofwhich 23 mg./kg. ofbody weight is the half-lethal dose (LD50)
for the mouse, and 22 mg./kg. that for the rat.
Using Wistar strain rats and white mice of our own breed, experimentation in
normal intact animals and animals with transplanted tumours showed the
daily therapeutic dose level to vary between 1.5 and 3 mg./kg. for the tumour-
bearing rat, and 3 and 5 mg./kg. for the tumour-bearing mouse. In testing the
compound against a spectrum of rat and mouse tumours, treatment, usually
with daily intraperitoneal injections, was begun when the tumours were from a
pea to a bean in size. A prolonged treatment not involving considerable loss of
weight was aimed at. After treatment varying in time with the strain oftumour,
the animals were killed, the tumours removed and measured, and the percentage
growth-inhibition was determined on the basis of the following formula:
Average weight of tumours in controls-Average weight of
~Inhibition ° tumours in experimentals x 100
Average weight of tumours in controls
In some experiments survival time was used as a measure of benefit from the
drug. In testing DBM against tumours in ascitic form, treatment was begun either
one or two days after inoculation of the ascites, or on the first signs of ascites
formation in the inoculated animal, and the degree of the inhibitory effect was
graded according to the difference in body weight between the treated and the
control animals.
The drug was subjected to detailed examinations for its effect on the blood
picture, the bone marrow, and the parenchymatous organs.
In most cases the effectiveness of DBM was compared with that of Degranol
(BCM).
RESULTS
Effect of DBM (R13) on transplantable tumours
1. The growth-inhibiting action on rat tumours was studied in a set of experi-
ments using Guerin carcinoma, Benevolenskaya sarcoma, and a subcutaneous
form ofYoshida sarcoma. In agreement with Druckrey and co-workers (1958), we
found the latter was just as useful as Yoshida ascites sarcoma in testing chemo-
therapeutic agents: rats inoculated with the tumour in ascitic form survived
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for an average 8 to 10 days, with only 1 to 3 ml. of ascitic fluid forming; sub-
cutaneously inoculated rats survived for 12 to 18 days.
The growth-inhibiting effect of DBM on the rat tumours involved in our
experiments is illustrated in Table I and Fig. 1 and 2.
Using Guerin tumour, DBM was tested for its effect upon survival time in
39 Wistar strain rats treated in three groups with an intraperitoneal daily dose
of 0 4, 1 0, and 2-0 mg./kg. of body weight, respectively; another 39 rats of the
same strain were left untreated to serve as controls; an additional 24 rats bearing
Guerin tumours were given from 4 to 12 mg. daily doses of Degranol per kg. of
body weight. Treatment was continued until the death of the last experimental
animal. In relation to the untreated controls, DBM was found to have prolonged
the survival time by from 8 to 15, and BCM by from 2 to 7 days.
2. For its effect on transplantable solid mouse tumours the compound was
studied on subcutaneously inoculated Ehrlich carcinoma and S-37 and S-180
(Crocker) sarcoma. The results obtained are summarized in Table II.
3. For its growth-inhibiting action in mouse tumours in ascitic form, DBM
was tested in Ehrlich carcinoma and Amytal sarcoma. The latter originates
from this Institute (JuhAsz, Balo and Kendrey, 1955); it is transplanted in
every 10 to 12 days, during which time 8 to 10 ml. of ascitic fluid develop in each
animal; the mice generally survive transplantation by from 14 to 18 days.
To every ml. of ascitic fluid drawn from them, 0-25 mg. of DBM and Degranol,
respectively, were added dissolved in 1 ml. saline under sterile conditions and the
mixture was kept in the thermostat at 37° C. for 45 minutes. Two groups of
10 white mice each were then inoculated with an equal amount of one and the
other of these mixtures, respectively, while in a third group of 10 controls each
animal was inoculated with a corresponding amount of a mixture of ascitic
fluid and sterile physiological NaCl incubated likewise at 37° C. for 45 minutes.
All the animals were kept under observation for 11 days with a view to finding
out to what extent under the identical conditions equal concentrations of the
two drugs were capable of depressing takes and inhibiting tumour growth. The
results ofdaily checks onthe changes ofbodyweightshowedthatwhilethe average
over-all gain was 7.10 g. in the control group, it amounted to 3.23 g. in the group
treated with DBM, and to 5.74 g. in that treated with Degranol; in other words,
an inhibitory effect of 44 per cent. was observed upon the action of DBM, and
of 19-2 per cent. upon that of Degranol.
Using Amytal ascites sarcoma, another experiment was carried out to deter-
mine the influence of DBM and Degranol, respectively, on the survival time of
mice. Fig. 3 shows that while seven consecutive daily doses of 4.85 mg. of DBM
per kg. of body weight resulted in prolongation of survival time, no appreciable
prolongation followed the administration of the same number of 21 mg. doses
of Degranol.
EXPLANATION OF PLATE
FIG. 1.-Showing 92 per cent growth inhibition on Gu6rin carcinoma after 19 doses of
2- 6 mg./kg. of DBM (R13).
FIG. 2.-Showing 93 per cent and 84 per cent growth inhibition on subcutaneously inoculated
Yoshida sarcoma after 9 doses of 1.75 mg./kg. of DBM (R13) and 10 mg./kg. of Degranol
(BCM), respectively.
FIG. 5.-Showing inhibition of development of Ehrlich ascites carcinoma by 7 daily doses of
4 85 mg./kg. of DBM (R13).
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On the growth of Ehrlich ascites carcinoma, 11 consecutive daily doses of
6-75 mg. ofDBM per kg. of body weight were found to have a marked inhibitory
effect, while the same number of 14 mg. doses ofDegranol failed to inhibit essen-
tially the growth of this tumour (Fig. 4).
10
mu8
r.4
46 0
$4
N) 4
A I
FIG. 3. Showing
DBM
--- R(M
rol rol
10 12 14 16 18 20 22 24 26 28 30
Daysofsurvivingafter transplantation
increase of survival time of mice inoculated with Amytal ascites sarcoma
treated with DBM (R13) or Degranol (BCM).
-**DBM
--4 BCM
-O---O- Control
7 9 11 13 15 17
after transplantation
FIG. 4.-Showing increase of weight of mice bearing Ehrlich ascites carcinoma following
treatment with DBM (R13) or Degranol (BCM).
In another experiment, in which animals bearing Ehrlich ascites tumours
were treated during 9 days on each of seven occasions with 4-85 mg. of DBM
per kg. ofbody weight, no ascites developed at all (Fig. 5). OfDegranol, the same
number of 21 mg. doses was required to achieve the identical effect.
Effect of DBM on blood picture, bone marrow, and parenchymatous organs
For its effect on peripheral blood DBM was studied in 16 rats of the Wistar
strain, eachweighing 150g. After their complete bloodpictures had beenprepared,
some normal animals were injected intraperitoneally on one occasion with a simple,
others with a threefold, yet others with a tenfold medium therapeutic dose (the
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simple dosis therapeutica being 1.75 mg./kg. of body weight). Twenty-four hours
later, there was no change in the number of erythrocytes at any dose levels;
the simple therapeutic dose was followed by minimal lymphopenia; the threefold
dose gave rise to significant lymphopenia and monocytopenia and relative
leukocytosis, though the white cell count remained normal. The tenfold dose
caused appreciable leukopenia, the lymphocytes disappeared almost completely
from the blood, the plasma of the retained ones becoming vacuolated and, in
addition, a marked decrease in the number of monocytes and a relative leuko-
cytosis were observed (Table III).
TABLE III.-Effect of a Single Intraperitoneal Dose of DBM Upon the Blood Cells
Number of Number of
Dose erythrocytes leukocytes
(mg./kg.) (106/c.mm.) (103/c.mm.) Poly. Ly. Mo. Eo.
1*75 . Before treatment . 6-4 8 2 . 42 . 55 . 2 . 1
After treatment . 7-8 . 9-2 . 43 . 53 . 4 . 0
5-25 . Before treatment . 8-5 . 10 7 . 36 . 59 . 3 . 2
After treatment . 7
- 9 9.1 . 62 . 37 . 0 . 1
175 . Before treatment . 8-.5 . 9-2 . 25 . 72 1 2
After treatment . 8-4 . 6-6 92 . 6 0 . 2
In animals given the medium therapeutic dose for 15 consecutive days, there
was no change in the red cell count, but the white cells fell to 5000 per c.mm.
from the normal ofabout 9000 per c.mm. generally counted in the control animals;
in the number of lymphocytes a substantial decrease was observed; relative
leukocytosis presented itself, associated with eosinophilia (Table IV).
TABLE IV.-Effect of Serial Intraperitoneal Treatment (15 Times) with DBM
Upon the Blood Cells ofRats
Daily dose Erythrocytes Leukocytes
(mg./kg.) (106/c.mm.) (103/c.mm.) Poly. Ly. Mo. Eo.
1 75 Before treatment 8-2 . 90 34 . 62 . 2 2
After treatment 8 3 . 5.0 . 45 46 . 3 . 6
For its action on bone marrow the compound was tested in normal intact
Wistar strain rats which, in 45 days, had been treated on 34 occasions with 1.75
mg. of DBM per kg. ofbody weight by the intraperitoneal route. This treatment
was followed by a slight decrease in the number of myeloid elements. In some
individual cases the haemopoietic colonies were seen to have ceded their place to
fatty bone marrow. The blood pictures ofthese animals revealed marked lympho-
penia, relative leukocytosis, and moderate eosinophilia. No pathological changes
were encountered in the myocardium, the lung, the kidney, and the adrenal
gland, but the spleen was found to have decreased in size, and the lymph follicles
were less than normal in number. Slight pulpar fibrosis was seen. In the liver
parenchymatous degeneration was observed, but no fatty degeneration or cellular
necrosis.
DISCUSSION
On the evidence of the results of our toxicity tests, the efficient but not toxic
dose ofDBM varies between 1.5 and 3.0 mg. perkg. ofbody weight for the tumour-
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bearing rat, and between 3 0 and 5 0 mg. for the tumour-bearing mouse. At
these dose levels, the animals will stand treatment for 10 to 12 consecutive days
without losing more than 6 to 12 per cent. in weight. The chemotherapeutic
index for DBM being
MTD MED -- 25,
it comes to fall between that for Degranol (50) and nitrogen mustard (10).
From our experimental findings the conviction accrues that DBM is a drug,
which exerts a marked inhibitory effect on tumour cells. Undoubtedly, it was
the most effective against Yoshida sarcoma, a tumour responding as a rule fairly
well to efficient chemotherapeutic agents. Equally remarkable was the effect it
appeared to have on Guerin cancer, the more so as malignant animal tumours
(Guerin and Ehrlich tumours) are conspicuous for the difficulty in influencing
their growth by means of therapeutic drugs. Not a single complete regression
was observed in animals inoculated with these tumours, unlike in cases of sub-
cutaneously implanted Yoshida sarcoma. Histologically, the small tumours
found in a few of our animals inoculated with Yoshida sarcoma and treated with
DBM could no longer be regarded as real tumours.
In animals bearing Gu6rin or Ehrlich carcinoma, we on a few occasions suc-
ceeded in maintaining for some considerable period of time a state in which there
was no perceptible tumour growth, and even several remissions took place.
Ifin such a state treatment was continued, the animals died after a time, displaying
toxic symptoms; if it was discontinued, the tumour started to grow again but
could not be depressed once more, not even by means of larger doses.
With the histological changes in tumours following treatment with DBM,
we propose to deal elsewhere.
SUMMARY
Twenty-three compounds prepared by linking nitrogen mustard with various
sugars were tested on various transplantable tumours for their capacity to inhibit
growth. The one designated as DBM (R13), the structural formula of which may
be represented as 1,6-di-(2-bromoethylamino)-1,6-dideoxy-D-mannitol dihydro-
bromide, was found to have a marked inhibitory effect on Guerin rat carcinoma,
subcutaneous form of Yoshida rat sarcoma, Benevolenskaya rat sarcoma, the
subcutaneous and ascitic forms of Ehrlich mouse carcinoma, Crocker and S-37
mouse sarcoma, and Amytal ascites sarcoma in the mouse. The drug is much
less toxic than nitrogen mustard and depresses tumour growth without causing
considerable loss of weight or toxic side effects. It is not without effect on peri-
pheral blood and the lymphatic organs. Following treatment with therapeutic
doses for some longer period of time, there is a reduction first in the lymphocyte
and then in the leukocyte count, the spleen diminishes in size, the lymph follicles
in it grow less in number, and fibrosis of the pulp is seen. Animal experiments
have shown this agent to be more effective than Degranol.
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